Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Severe Obstructive Sleep Apnea Doubles Risk of Heart Attack Death

XTALKS VITALS NEWS

Sleep Apnea

A recent study published in the American Heart Association’s (AHA) journal, Circulation, found that both moderate and severe forms of sleep apnea were associated with a higher risk of cardiovascular disease.

Share this!

February 9, 2017 | by Sarah Hand, M.Sc.

February is American Heart Month, and according to the National Healthy Sleep Awareness Project, leaving severe obstructive sleep apnea untreated raises an individual’s risk of suffering a fatal heart attack. In order to raise public awareness of this risk, the associations – in partnership with the American Academy of Sleep Medicine (AASM), the Centers for Disease Control and Prevention (CDC) and the Sleep Research Society (SRS) – are launching an ad campaign called “Sleep Apnea Hurts Hearts.”

A recent study published in the American Heart Association’s (AHA) journal, Circulation, found that both moderate and severe forms of sleep apnea were associated with a higher risk of cardiovascular disease. Treatment for sleep apnea often involves the use of a continuous positive airway pressure (CPAP) device.



“Obstructive sleep apnea is a dangerous disease that can severely damage your heart if left untreated,” said Dr. Ronald Chervin, president of the AASM and a spokesperson for the National Healthy Sleep Awareness Project. “With millions of sufferers remaining undiagnosed, it is critical to raise nationwide awareness about obstructive sleep apnea so that it can be treated with CPAP therapy, which can reduce the risk of cardiovascular death.”

In the context of the ad campaign, the word HEARTS is used as an acronym which names all of the negative health consequences of uncontrolled obstructive sleep apnea. The condition increases the risk of heart failure, elevated blood pressure, atrial fibrillation, resistant hypertension, type 2 diabetes and stroke.

“It is clear that untreated, severe obstructive sleep apnea may have a devastating impact on heart health,” said Dr. Janet B. Croft, senior chronic disease epidemiologist in CDC's Division of Population Health. “Anyone who has symptoms of sleep apnea such as loud snoring in addition to obesity and a heart problem or high blood pressure should discuss their risk for sleep apnea with their doctor.”

Obstructive sleep apnea is characterized by the collapse of the upper airway during sleep, and affects almost 30 million Americans. Obesity, high blood pressure, snoring and fatigue are all risk factors and warning signs of sleep apnea, according to the National Healthy Sleep Awareness Project.


Keywords: Sleep Apnea, Heart Attack, Heart Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets from #AAIC17

REGISTER FOR THESE WEBINARS

Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.